Chris has over 24 years of collective consulting and Wall Street experience as a life science fund manager and sell-side biotechnology analyst. Before joining Blueprint in 2010, he spent six years as Managing Director and Co-Portfolio Manager for J&W Seligman’s HealthSpectrum Fund, where he was responsible for >$700M in assets. Prior to that, he was Portfolio Manager of EGM Capital’s Medtech Fund, specializing in public and private investments in emerging life science companies. Chris’ sell-side analyst experience includes serving as Biotechnology Research Analyst for Prudential Vector Healthcare Group and as Vice President, Research (Biotechnology) at Wells Fargo Securities. Chris earned a B.S. in Chemical Engineering with an emphasis on Bioengineering and an M.S. in Chemical Engineering from the University of California at Los Angeles, CA. He has authored numerous Wall Street sell-side and scientific publications.
Hershel has spent the last 20 years working with emerging private and public companies to secure key financial and business relationships. Prior experience includes serving as a Director of the Trout Group, an investor relations firm serving the life science sector; and Idealab, a venture capital firm that incubates technology-based companies. Through the years, Hershel has remained active in No Mayo, an organization he founded in 1990 that supports music education in public schools. While at No Mayo, he secured corporate partnerships and oversaw the organization’s donations to public high schools in San Francisco, Los Angeles, and New York City. Partnership highlights include: Sony Music Alliance Capital and Booze Allen Hamilton. Hershel has a B.S. in Business and English from Skidmore College in Saratoga Springs, NY.
Malini heads up Blueprint’s East Coast operations. She joined Blueprint after a 10-year period of investing in biotech and pharma stocks at institutional funds such as CR Intrinsic Investors/SAC Capital where she was the senior analyst responsible for a biotech portfolio of $800MM in assets. After SAC Capital, Malini ran a $500MM biotech equity and convertible portfolio at K Street Capital as Jr. Portfolio Manager. Prior to Malini's foray into Wall Street, she worked as a senior consultant for Genentech Bio Oncology spearheading all medical and scientific communications towards the Phase III clinical trials and launch of Avastin in the U.S. Malini also brings to Blueprint independent consultancy experience having launched Bio Intuition LLC, a provider of topic specific "deep-dive” analyses to both large institutional investors and small biotech companies. The majority of Bio Intuition's revenues provide financial and educational support to families of children with autism. Malini has a Ph.D. in molecular oncology from Columbia University with a doctoral publication in the medical journal "Science" and an M.S. with a double major in Math and Microbiology from the University of Bombay, India.